BiotechTube

BAY1834845 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pelvic Inflammatory Disease

Conditions

Pelvic Inflammatory Disease

Trial Timeline

Feb 13, 2017 → Mar 29, 2018

NCT ID
NCT03054402

About BAY1834845 + Placebo

BAY1834845 + Placebo is a phase 1 stage product being developed by Bayer for Pelvic Inflammatory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03054402. Target conditions include Pelvic Inflammatory Disease.

What happened to similar drugs?

3 of 6 similar drugs in Pelvic Inflammatory Disease were approved

Approved (3) Terminated (1) Active (3)
✅Solifenacin + PlaceboAstellas PharmaApproved
✅Conjugated Estrogens Cream + Placebo CreamPfizerApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄AzithromycinPfizerPhase 3
🔄Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
🔄Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03054402Phase 1Completed

Competing Products

11 competing products in Pelvic Inflammatory Disease

See all competitors
ProductCompanyStageHype Score
Solifenacin + PlaceboAstellas PharmaApproved
35
BGS649 + PlaceboNovartisPhase 2
27
Tanezumab + PlaceboPfizerPhase 2
35
AzithromycinPfizerPhase 3
40
Vaginal estrogen + PlaceboPfizerPre-clinical
18
Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tabletPfizerPhase 2
27
Conjugated Estrogens Cream + Placebo CreamPfizerApproved
43
Ofloxacin + Avelox (Moxifloxacin, BAY12-8039)BayerPhase 3
37
Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & MetronidazoleBayerPhase 3
37
Dienogest (BAY86-5258, Visanne)BayerPre-clinical
23
Sevoflurane + propofol + remifentanilBaxterApproved
40